Free Trial
LON:TCF

Theracryf (TCF) Share Price, News & Analysis

GBX 0.25 -0.02 (-8.73%)
As of 09:59 AM Eastern

About Theracryf Stock (LON:TCF)

Key Stats

Today's Range
0.25
0.28
50-Day Range
0.20
0.28
52-Week Range
0.20
1.25
Volume
64,778 shs
Average Volume
3.20 million shs
Market Capitalization
£1.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

Receive TCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theracryf and its competitors with MarketBeat's FREE daily newsletter.

TCF Stock News Headlines

Theracryf Plc (TCF.L)
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…
Theracryf PLC Share Chat (TCF)
See More Headlines

TCF Stock Analysis - Frequently Asked Questions

Theracryf's stock was trading at GBX 0.54 on January 1st, 2025. Since then, TCF stock has decreased by 53.3% and is now trading at GBX 0.25.
View the best growth stocks for 2025 here
.

Theracryf Plc (LON:TCF) released its earnings results on Thursday, November, 28th. The company reported ($29.00) earnings per share (EPS) for the quarter. Theracryf had a negative net margin of 792.17% and a negative trailing twelve-month return on equity of 99.97%.

Shares of TCF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Company Calendar

Last Earnings
11/28/2024
Today
5/30/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
Banking
Current Symbol
LON:TCF
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£5.45 million
Net Margins
-792.17%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£687,674.98
Price / Cash Flow
N/A
Book Value
GBX 0.85 per share
Price / Book
0.29

Miscellaneous

Free Float
N/A
Market Cap
£1.20 million
Optionable
N/A
Beta
1.42
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (LON:TCF) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners